GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GI Innovation Inc (XKRX:358570) » Definitions » COGS-to-Revenue

GI Innovation (XKRX:358570) COGS-to-Revenue : 0.00 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is GI Innovation COGS-to-Revenue?

GI Innovation's Cost of Goods Sold for the three months ended in Mar. 2025 was ₩0.0 Mil. Its Revenue for the three months ended in Mar. 2025 was ₩212.3 Mil.

GI Innovation's COGS to Revenue for the three months ended in Mar. 2025 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. GI Innovation's Gross Margin % for the three months ended in Mar. 2025 was N/A%.


GI Innovation COGS-to-Revenue Historical Data

The historical data trend for GI Innovation's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GI Innovation COGS-to-Revenue Chart

GI Innovation Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial - - - - -

GI Innovation Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GI Innovation COGS-to-Revenue Calculation

GI Innovation's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 24.281
=0.00

GI Innovation's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 212.266
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GI Innovation  (XKRX:358570) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

GI Innovation's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 212.266
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


GI Innovation COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of GI Innovation's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


GI Innovation Business Description

Traded in Other Exchanges
N/A
Address
Songpa-daero 167, Room 1116 of A-dong, Songpa-gu, Seoul, KOR, 05855
GI Innovation Inc is a bio-venture company that researches and develops protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and developing a fusion protein using the GI-SMART platform.

GI Innovation Headlines

No Headlines